Focus May Be on Whether New Price Cutting Rule for Long-Listed Drugs Should Apply Only to Those Granted Premium

Speaking with reporters on December 7, Yoshiaki Kamoya, who chairs the Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) NHI Drug Price Study Committee and serves as a member on the Central Social Insurance Medical Council’s (CSIMC) Expert Subcommittee on...read more